Dechra Pharmaceuticals Limited, a Northwich, Cheshire, UK-based provider of a veterinary pharmaceuticals business, acquired Invetx Inc., a Boston, MA-base company which specializes in protein-based therapeutics for animal health, for up to $520M.
The acquisition remains subject to antitrust approval and other customary closing conditions.
In addition to the Invetx pipeline, Dechra will gain access to the company’s species-specific, half-life extension platform, which extends duration of drug activity and enables longer intervals between treatment, offering greater convenience and improved compliance for veterinarians, owners and their pets.
Led by Juergen Horn, Dr.med.vet., Ph.D., chief executive officer and co-founder, Invetx specializes in creating novel, protein-based animal health therapeutics to transform standards of care in veterinary medicine. It leverages an integrated biotechnology platform for the discovery, development, and manufacturing of veterinary monoclonal antibodies, and is developing a diverse product pipeline addressing chronic and severe diseases in companion animals. Invetx has raised $86 million since 2018, including investors F-Prime Capital, Novo Holdings, GV, Eight Roads, Anterra Capital, Casdin Capital and funds managed by Tekla Capital Management, LLC. Strategic investment partners include AbCellera, a global technology company specializing in antibody discovery located in Vancouver, BC, and WuXi Biologics, a global company with leading biologics technology platforms.
Led by Jesper Nordengaard, chief executive officer, Dechra is a provider of a veterinary pharmaceuticals and related products business. Its expertise is in the development, manufacture, and sales and marketing of products, exclusively for veterinarians, to support the sustainable improvement of animal health and welfare worldwide.
FinSMEs
19/07/2024